Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAutolus Therapeutics Ltd

Autolus Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.2525 USD -0.07 ( 5.11%)
Last update at 2026-11-11T20:59:00Z
VOLUME
3605508
Market Cap
412.52M

Momentum Score

…

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.20
Low
1.33
High
52 Week Price Range
1.15
Low
2.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Autolus Therapeutics is a clinical-stage company developing engineered T-cell (CAR-T) therapies for hematologic and solid tumors aimed at improving persistence and safety. Long-term growth drivers include pivotal clinical trial readouts, pipeline expansion and strategic partnerships that may support progression toward commercialization.

Principal risks include high clinical and regulatory failure probability, stiff competition from established CAR-T companies, complex and costly manufacturing with significant cash burn and potential dilution, and uncertain commercial uptake if products gain approval.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.32
Dividend Yield
-
Revenue TTM
1.08M
Revenue Per Share
0.03
Gross Profit TTM
-26.48M
Debt / Equity
1.97
ROE
-29.62%
Net Debt
247.45M
ROCE
-54.58%
Diluted EPS TTM
-1.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Income before tax -296.85M -219.13M -208.40M -148.57M -173.21M
Net income -287.53M -220.66M -208.38M -148.84M -148.84M
Selling general administrative 131.87M 101.09M 46.74M 31.90M 31.90M
Selling and marketing expenses - - 1.10M - -
Gross profit -21.03M -130.90M 1.70M 6.19M 6.19M
Reconciled depreciation 9.81M 7.72M 6.44M 7.42M 7.42M
Ebit -281.44M -240.79M -163.34M -139.66M -163.78M
Ebitda -271.60M -233.07M -156.77M -132.24M -156.36M
Depreciation and amortization 9.84M 7.72M 6.57M 7.42M 7.42M
Operating income -281.44M -241.43M -179.70M -142.89M -163.78M
Other operating expenses 357.00M 251.55M 181.40M 149.09M 173.72M
Interest expense 36.76M 9.29M 45.07M 8.90M 8.90M
Tax provision 1.97M 1.53M -17.50M -24.37M -24.37M
Interest income 18.98M 32.35M 11.92M 1.71M 1.71M
Net interest income -17.69M 23.06M -6.47M -7.20M -7.20M
Income tax expense 1.97M 1.53M -0.02M 0.27M -24.37M
Total revenue 75.56M 10.12M 1.70M 6.19M 6.19M
Total operating expenses 260.41M 110.53M 181.40M 149.09M 173.72M
Cost of revenue 96.37M 141.02M 6.57M 137.22M -
Total other income expense net -15.41M 22.29M -28.70M -5.67M -9.42M
Net income from continuing ops -287.53M -220.66M -158.16M -148.84M -148.84M
Net income applicable to common shares - - - -148.84M -148.84M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-09-30 2022-12-31
Total assets 589.07M 782.73M 375.38M 375.38M 490.27M
Intangible assets 19.81M 12.37M - - -
Other current assets 26.74M 20.53M 34.69M 35.74M 14.36M
Total liab 410.94M 355.40M 263.91M 263.91M 191.60M
Total stockholder equity 178.13M 427.32M 111.47M 111.47M 298.67M
Other current liab 55.79M 52.18M 39.58M 44.74M 40.80M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1386.75M -1099.22M -878.56M -878.56M -670.18M
Other liab - - - - 126.02M
Other assets - - 0.00M 0.00M 6.08M
Cash 104.13M 227.38M 239.57M 239.57M 382.44M
Total current liabilities 73.44M 60.74M 44.74M 44.74M 46.37M
Current deferred revenue - - -5.16M -5.16M -
Net debt 247.45M -174.75M -186.60M -186.60M -358.18M
Short term debt 14.56M 3.00M 5.05M 5.05M 5.04M
Short long term debt total 351.59M 52.63M 52.97M 52.97M 24.26M
Other stockholder equity 1570.11M 1555.71M 1019.02M 1019.02M 1007.74M
Property plant equipment - - - - 58.42M
Total current assets 435.92M 660.93M 275.30M 275.30M 425.77M
Net tangible assets - - - - 298.67M
Short term investments 196.58M 360.64M 0.00M - -
Net receivables 75.26M 48.24M 1.05M 24.54M 28.98M
Inventory 33.21M 4.14M -23.50M -24.54M 14.16M
Accounts payable 3.08M 1.97M 0.10M 0.10M 0.53M
Accumulated other comprehensive income -5.36M -29.17M -28.99M -28.99M -38.90M
Non currrent assets other 1.28M 1.13M 1.36M 1.36M 4.01M
Non current assets total 153.15M 121.80M 100.08M 100.08M 64.50M
Capital lease obligations 71.39M 52.63M 52.97M 52.97M 24.26M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-09-30
Investments 185.59M -394.55M -10.99M -10.84M -10.84M
Change to liabilities - - - 0.02M 0.02M
Total cashflows from investing activities 158.46M -394.55M -10.99M -10.84M -10.84M
Total cash from financing activities -4.34M 589.55M -0.88M 223.61M 223.61M
Change to operating activities - - - 3.95M 3.95M
Net income -287.53M -220.66M -208.38M -148.84M -148.84M
Change in cash -123.17M -11.53M -142.43M 72.08M 72.08M
Begin period cash flow 228.81M 240.34M 382.76M 310.68M 310.68M
End period cash flow 105.64M 228.81M 240.34M 382.76M 382.76M
Total cash from operating activities -283.57M -206.27M -145.59M -112.31M -112.31M
Issuance of capital stock 0.00M 549.98M 0.00M 163.85M 163.85M
Depreciation 9.81M 7.72M 6.57M 7.42M 7.42M
Other cashflows from investing activities -27.13M -12.74M - - -
Change to inventory -40.34M -4.23M 0.00M - -
Change to account receivables -24.21M 0.00M - - -
Other cashflows from financing activities -4.34M 39.58M -0.88M 59.76M 59.76M
Change to netincome - - - 25.14M 25.14M
Capital expenditures 19.09M 34.82M 10.99M 10.84M 10.84M
Change in working capital -52.11M -23.66M 0.29M 3.97M 3.97M
Stock based compensation 14.44M 15.47M 11.20M 12.01M 12.01M
Other non cash items 32.10M 15.04M 45.72M 13.39M 13.39M
Free cash flow -303.32M -241.09M -156.57M -123.15M -123.15M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AUTL
Autolus Therapeutics Ltd		 -0.07
5.11%		 1.25 - - 382.50 2.38 2.57 0.03
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Autolus Therapeutics Ltd

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

The Mediaworks, London, United Kingdom, W12 7FP

44 20 3829 6230

https://www.autolus.com

752

Name Title Year Born
Dr. Christian Martin Itin Ph.D. CEO & Director 1964
Dr. Martin Pule M.D., MBBS Founder, Sr. VP & Chief Scientific Officer 1972
Mr. Christopher Vann Sr. VP & COO 1965
Mr. David Brochu Sr. VP & Chief Technical Officer 1956
Mr. Andrew J. Oakley ACA, BEcon, MBA Sr. Advisor 1962
Mr. Brent Rice Sr. VP, Chief Commercial Officer & Site Head of US 1966
Dr. Edgar E. W. Braendle M.D., Ph.D. Sr. VP & Chief Devel. Officer 1960
Dr. Lucinda Crabtree Ph.D. Chief Financial Officer NA
Ms. Olivia Manser Director of Investor Relations NA
Dr. Chris Williams Sr. VP of Corp. Devel. 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…